310.60
+2.71%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gubra A/S
Its shares trade on Nasdaq Copenhagen under the ticker GUBRA.CO. It has been listed since 4 April 2023. In the fiscal year to 31 December 2025, it reported revenue of DKK 2.64bn and net income of DKK 1.69bn. At that date it held total assets of DKK 1.32bn and shareholders' equity of DKK 1.15bn.
Gubra ApS operates as biotechnology company. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 4 Apr 2023
- Employees
- 200
- Website
- gubra.dk ↗
Leadership
Pay as last reported
- Ms. Monika LesslIndependent Chairman of the Board, since 2025
- Mr. Henrik BlouChief Executive OfficerDKK 23.0m
- Mr. Alexander Martensen-LarsenIndependent Deputy Chairman of the Board
- Mr. Jacob JelsingCo-Founder, Director, since 2008
- Mr. Niels VrangCo-Founder, Director, since 2008DKK 1.6m
- Mr. Kristian BorbosChief Financial OfficerDKK 598,664
- Ms. Astrid HaugIndependent Board Member
- Dr. Claudia MitchellIndependent Board Member
- Dr. Arndt SchotteliusIndependent Board Member
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gubra ApS leverages automation and AI for high-margin pre-clinical services in metabolic diseases.
- The CRO Segment provides specialized services in diabetes and obesity with strong profitability.
- Gubra's drug discovery engine focuses on peptide-based solutions for fibrotic diseases.
Weaknesses
- Gubra ApS has only 200 employees, limiting scalability in global markets.
- The company is listed on the Danish stock exchange since April 2023, lacking international recognition.
- Gubra's operations are concentrated in Hoersholm, DK, restricting geographic diversification.
Opportunities
- Expanding into chronic kidney disease services within the CRO Segment offers new revenue streams.
- Partnerships in metabolic disease drug discovery could attract significant investment.
- Growing demand for AI-driven biotech solutions in Europe presents expansion potential.
Threats
- Competition in metabolic disease research may reduce profit margins over time.
- Regulatory changes in the Danish biotech sector could impact operations.
- Economic downturns might affect funding for pre-clinical contract research services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.